List of Chapters/Sections(Table Of Content)
1 Study Coverage
1.1 Hemoglobinopathies Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Thalassemia Therapy
1.2.3 Sickle Cell Disease(SCD) Therapy
1.2.4 Other Therapy
1.3 Market by Application
1.3.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Alpha Thalassemia
1.3.3 Beta thalassemia
1.3.4 Sickle Cell Disease
1.3.5 Hb Variants Diseases
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Hemoglobinopathies Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Hemoglobinopathies Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Hemoglobinopathies Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Hemoglobinopathies Drugs Sales by Region
2.4.1 Global Hemoglobinopathies Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Hemoglobinopathies Drugs by Region (2023-2028)
2.5 Global Hemoglobinopathies Drugs Revenue by Region
2.5.1 Global Hemoglobinopathies Drugs Revenue by Region (2017-2022)
2.5.2 Global Hemoglobinopathies Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Hemoglobinopathies Drugs Sales by Manufacturers
3.1.1 Global Top Hemoglobinopathies Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Hemoglobinopathies Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hemoglobinopathies Drugs in 2021
3.2 Global Hemoglobinopathies Drugs Revenue by Manufacturers
3.2.1 Global Hemoglobinopathies Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Hemoglobinopathies Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Hemoglobinopathies Drugs Revenue in 2021
3.3 Global Hemoglobinopathies Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Hemoglobinopathies Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Hemoglobinopathies Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hemoglobinopathies Drugs Sales by Type
4.1.1 Global Hemoglobinopathies Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Hemoglobinopathies Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Hemoglobinopathies Drugs Sales Market Share by Type (2017-2028)
4.2 Global Hemoglobinopathies Drugs Revenue by Type
4.2.1 Global Hemoglobinopathies Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Hemoglobinopathies Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Hemoglobinopathies Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Hemoglobinopathies Drugs Price by Type
4.3.1 Global Hemoglobinopathies Drugs Price by Type (2017-2022)
4.3.2 Global Hemoglobinopathies Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Hemoglobinopathies Drugs Sales by Application
5.1.1 Global Hemoglobinopathies Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Hemoglobinopathies Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Hemoglobinopathies Drugs Sales Market Share by Application (2017-2028)
5.2 Global Hemoglobinopathies Drugs Revenue by Application
5.2.1 Global Hemoglobinopathies Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Hemoglobinopathies Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Hemoglobinopathies Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Hemoglobinopathies Drugs Price by Application
5.3.1 Global Hemoglobinopathies Drugs Price by Application (2017-2022)
5.3.2 Global Hemoglobinopathies Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Hemoglobinopathies Drugs Market Size by Type
6.1.1 North America Hemoglobinopathies Drugs Sales by Type (2017-2028)
6.1.2 North America Hemoglobinopathies Drugs Revenue by Type (2017-2028)
6.2 North America Hemoglobinopathies Drugs Market Size by Application
6.2.1 North America Hemoglobinopathies Drugs Sales by Application (2017-2028)
6.2.2 North America Hemoglobinopathies Drugs Revenue by Application (2017-2028)
6.3 North America Hemoglobinopathies Drugs Market Size by Country
6.3.1 North America Hemoglobinopathies Drugs Sales by Country (2017-2028)
6.3.2 North America Hemoglobinopathies Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Hemoglobinopathies Drugs Market Size by Type
7.1.1 Europe Hemoglobinopathies Drugs Sales by Type (2017-2028)
7.1.2 Europe Hemoglobinopathies Drugs Revenue by Type (2017-2028)
7.2 Europe Hemoglobinopathies Drugs Market Size by Application
7.2.1 Europe Hemoglobinopathies Drugs Sales by Application (2017-2028)
7.2.2 Europe Hemoglobinopathies Drugs Revenue by Application (2017-2028)
7.3 Europe Hemoglobinopathies Drugs Market Size by Country
7.3.1 Europe Hemoglobinopathies Drugs Sales by Country (2017-2028)
7.3.2 Europe Hemoglobinopathies Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hemoglobinopathies Drugs Market Size by Type
8.1.1 Asia Pacific Hemoglobinopathies Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Hemoglobinopathies Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Hemoglobinopathies Drugs Market Size by Application
8.2.1 Asia Pacific Hemoglobinopathies Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Hemoglobinopathies Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Hemoglobinopathies Drugs Market Size by Region
8.3.1 Asia Pacific Hemoglobinopathies Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Hemoglobinopathies Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Hemoglobinopathies Drugs Market Size by Type
9.1.1 Latin America Hemoglobinopathies Drugs Sales by Type (2017-2028)
9.1.2 Latin America Hemoglobinopathies Drugs Revenue by Type (2017-2028)
9.2 Latin America Hemoglobinopathies Drugs Market Size by Application
9.2.1 Latin America Hemoglobinopathies Drugs Sales by Application (2017-2028)
9.2.2 Latin America Hemoglobinopathies Drugs Revenue by Application (2017-2028)
9.3 Latin America Hemoglobinopathies Drugs Market Size by Country
9.3.1 Latin America Hemoglobinopathies Drugs Sales by Country (2017-2028)
9.3.2 Latin America Hemoglobinopathies Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hemoglobinopathies Drugs Market Size by Type
10.1.1 Middle East and Africa Hemoglobinopathies Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Hemoglobinopathies Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Hemoglobinopathies Drugs Market Size by Application
10.2.1 Middle East and Africa Hemoglobinopathies Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Hemoglobinopathies Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Hemoglobinopathies Drugs Market Size by Country
10.3.1 Middle East and Africa Hemoglobinopathies Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Hemoglobinopathies Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Gamida Cell
11.1.1 Gamida Cell Corporation Information
11.1.2 Gamida Cell Overview
11.1.3 Gamida Cell Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Gamida Cell Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gamida Cell Recent Developments
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Corporation Information
11.2.2 Alnylam Pharmaceuticals Overview
11.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Alnylam Pharmaceuticals Recent Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Overview
11.3.3 Biogen Idec Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biogen Idec Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biogen Idec Recent Developments
11.4 Sangamo BioSciences Inc.
11.4.1 Sangamo BioSciences Inc. Corporation Information
11.4.2 Sangamo BioSciences Inc. Overview
11.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sangamo BioSciences Inc. Recent Developments
11.5 Genetix Pharmaceuticals/Bluebird Bio
11.5.1 Genetix Pharmaceuticals/Bluebird Bio Corporation Information
11.5.2 Genetix Pharmaceuticals/Bluebird Bio Overview
11.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Genetix Pharmaceuticals/Bluebird Bio Recent Developments
11.6 Global Blood Therapeutics Inc.
11.6.1 Global Blood Therapeutics Inc. Corporation Information
11.6.2 Global Blood Therapeutics Inc. Overview
11.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Global Blood Therapeutics Inc. Recent Developments
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Corporation Information
11.7.2 Pfizer Inc. Overview
11.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Pfizer Inc. Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer Inc. Recent Developments
11.8 Mast Therapeutics
11.8.1 Mast Therapeutics Corporation Information
11.8.2 Mast Therapeutics Overview
11.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Mast Therapeutics Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Mast Therapeutics Recent Developments
11.9 Emmaus Life Sciences, Inc.
11.9.1 Emmaus Life Sciences, Inc. Corporation Information
11.9.2 Emmaus Life Sciences, Inc. Overview
11.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Emmaus Life Sciences, Inc. Recent Developments
11.10 Prolong Pharmaceuticals
11.10.1 Prolong Pharmaceuticals Corporation Information
11.10.2 Prolong Pharmaceuticals Overview
11.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Prolong Pharmaceuticals Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Prolong Pharmaceuticals Recent Developments
11.11 Celgene Corporation
11.11.1 Celgene Corporation Corporation Information
11.11.2 Celgene Corporation Overview
11.11.3 Celgene Corporation Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Celgene Corporation Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Celgene Corporation Recent Developments
11.12 HemaQuest Pharmaceuticals
11.12.1 HemaQuest Pharmaceuticals Corporation Information
11.12.2 HemaQuest Pharmaceuticals Overview
11.12.3 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 HemaQuest Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hemoglobinopathies Drugs Industry Chain Analysis
12.2 Hemoglobinopathies Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hemoglobinopathies Drugs Production Mode & Process
12.4 Hemoglobinopathies Drugs Sales and Marketing
12.4.1 Hemoglobinopathies Drugs Sales Channels
12.4.2 Hemoglobinopathies Drugs Distributors
12.5 Hemoglobinopathies Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Hemoglobinopathies Drugs Industry Trends
13.2 Hemoglobinopathies Drugs Market Drivers
13.3 Hemoglobinopathies Drugs Market Challenges
13.4 Hemoglobinopathies Drugs Market Restraints
14 Key Findings in The Global Hemoglobinopathies Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
